Sagility India Limited, a provider of healthcare-focused business solutions, has reported robust financial results for the fourth quarter and full financial year ended March 31, 2025. With a strategic focus on U.S. healthcare clients, the company recorded double-digit growth across revenue, EBITDA, and profit, reflecting strong demand for its technology-enabled services. Its consolidated revenue for FY25 reached ₹55,699 million, translating to a 17.2% year-on-year increase. Equally significant was its adjusted PAT (profit after tax), which rose 37.5% to ₹8,107 million, highlighting operational efficiency and strategic execution during the year.
In Q4 FY25, Sagility delivered revenue of ₹15,685 million, marking a 22.2% year-on-year rise. Adjusted EBITDA for the quarter reached ₹4,042 million, representing 25.8% of revenue and indicating strong margin discipline. The company’s Q4 adjusted PAT grew 45.2% year-on-year to ₹2,398 million, while adjusted EPS stood at ₹0.51.
These financials reinforce Sagility’s sustained growth trajectory, supported by domain-specific focus, diversified client engagement across payer and provider verticals, and expansion into mid-market healthcare plans.
What Are the Key Financial Metrics Underpinning Sagility’s FY25 Growth?
Sagility’s full-year performance showcased across-the-board improvements. The company’s adjusted EBITDA stood at ₹14,685 million, up 28.4% from FY24, representing 26.4% of revenue. Meanwhile, adjusted PAT improved from ₹5,896 million in FY24 to ₹8,107 million, a 37.5% gain, with PAT margin expanding to 14.6% of revenue from 12.4% a year earlier.
Adjusted EPS rose to ₹1.76 for the full year, reflecting a 27.7% growth over the previous year. Operational cash flow conversion remained healthy, with operating cash flow (OCF) to EBITDA ratio at 89.7%, demonstrating cash discipline.
From a vertical split, revenue from the payer segment rose to ₹49,775 million in FY25, while provider-related revenue increased by 27.9% to ₹5,924 million, indicating rising traction among healthcare providers. EBITDA margin improved slightly to 24.3% despite macroeconomic pressures, while profit before tax more than tripled year-over-year to ₹7,602 million from ₹2,417 million, driven by scale and internal efficiencies.
How Has Sagility’s Strategic Expansion, Including BroadPath Acquisition, Contributed?
A highlight of FY25 was the strategic acquisition of BroadPath, a U.S.-based healthcare services provider. Funded entirely through internal accruals, the acquisition bolsters Sagility’s footprint in mid-market health plans and adds capabilities in payer operations, particularly in payment integrity and customer service.
Management has highlighted promising early signs of cross-sell synergies from the BroadPath integration. Sagility’s strategy to broaden its client base while enhancing service differentiation through automation and GenAI-enabled offerings aligns well with the structural shifts in the U.S. healthcare outsourcing space.
This acquisition complements the company’s existing relationships with six of the top ten U.S. payers, deepening Sagility’s embeddedness in client operations while expanding margin-accretive offerings to smaller, fast-growing health plans.
What Role Did Technology-Enabled Services Play in Sagility’s FY25 Performance?
Sagility’s emphasis on digital transformation, including automation, analytics, and generative AI (GenAI), continues to be a defining pillar of its growth strategy. The company is increasingly using these technologies to strengthen client engagement, reduce administrative costs, and improve clinical and financial outcomes for U.S. healthcare stakeholders.
This focus has helped Sagility transition from a traditional BPO vendor to a strategic partner offering end-to-end managed services in healthcare. The company’s growing use of GenAI in repetitive administrative tasks, claims processing, and patient communication is attracting both incumbent and new clients seeking scalable digital solutions.
CEO Ramesh Gopalan underscored that technology-enabled services are helping Sagility win new deals and deepen relationships with current clients, especially as healthcare payers and providers pursue scalable transformation.
What Operational Highlights Supported Sagility’s Growth in FY25?
Sagility added 10 new global delivery sites during FY25, taking its total to 33 across five countries, including India, the U.S., the Philippines, Colombia, and Jamaica. This expansion enhances delivery redundancy and localizes support for diverse healthcare clients.
The company also onboarded 38 new clients during the year—up from 13 the previous year—demonstrating strong market momentum. Client concentration continued to moderate, with the top five clients accounting for 77.9% of revenue, compared to 79.2% in FY24 and 80.6% in FY23.
Employee strength stood at 39,409 as of March 2025, up 12.5% year-over-year, in line with business growth. Voluntary attrition averaged 27.5% in FY25, broadly steady compared to 27.2% in FY24.
How Is Sagility Positioning Itself as a Sustainability-Focused and Inclusive Employer?
Beyond financial performance, Sagility advanced its sustainability agenda during FY25. The Science Based Targets initiative (SBTi) validated the company’s emission reduction goals as aligned with climate science, particularly across scope 1 and 2 emissions. This milestone reflects growing ESG alignment with clients’ procurement expectations.
The company also received multiple workplace accolades. These included the “Onboarding Program of the Year” at the Empire Forums L&D Summit and the “Best Organization for Women 2025” award from ET Now, underscoring Sagility’s commitment to employee experience, DEI (diversity, equity, and inclusion), and talent retention.
What Is the Sentiment Around Sagility Stock and Future Outlook?
Sagility India’s stock performance is reflective of growing investor confidence in its margin expansion, client diversification, and digital enablement strategy. The adjusted EPS more than doubled on a basic level in FY25, while adjusted metrics indicate steady core earnings progression.
Market sentiment appears positive, with analysts likely to revise revenue and margin forecasts upward in light of strong FY25 performance and the BroadPath synergy potential. Institutional investors may also view Sagility favorably, given its self-funded acquisition, positive cash flow, and mid-double-digit revenue growth amid global macro uncertainty.
Buy-side sentiment may trend toward “accumulate” or “buy” as Sagility maintains sector-leading EBITDA margins and continues client expansion in a consolidating healthcare BPO landscape. Investor interest is further bolstered by the company’s deep relationships with top U.S. payers, its differentiated automation capabilities, and its proven execution track record.
What Lies Ahead for Sagility in FY26?
Looking forward, Sagility aims to deepen its client engagement across both payer and provider verticals, leveraging GenAI, analytics, and automation to offer more transformative solutions. With demand rising for managed healthcare services that combine cost efficiency with clinical precision, Sagility’s end-to-end domain expertise provides a strong competitive advantage.
Management has reiterated its commitment to sustainable, margin-accretive growth through operational discipline, technology-driven innovation, and continued geographic expansion. With 33 global delivery centres and a growing footprint in high-potential health plans, Sagility appears well-positioned to capture new market share in FY26 and beyond.
As Sagility continues to align its offerings with U.S. healthcare reform priorities—especially around reducing administrative burden and improving population health outcomes—it is expected to remain a key player in outsourced healthcare operations. Institutional activity and analyst coverage will be closely watched in coming quarters, as investors assess performance consistency and execution on strategic priorities.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
